Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other 1

Conditions

Cardiotoxicity 11Breast Neoplasms 8Neoplasms 3Heart Failure 3Lymphoma, Follicular 2Heart Diseases 2Cardiovascular Diseases 2Ventricular Dysfunction, Left 1Ventricular Dysfunction 1Thoracic Neoplasms 1Radiation Injuries 1Prostatic Neoplasms 1Obesity 1Myeloproliferative Disorders 1Multiple Myeloma 1Metabolic Syndrome 1Memory Disorders 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Breast and Ovarian Cancer Syndrome 1Dyspnea 1Dyslipidemias 1Diabetes Mellitus, Type 1 1Cognitive Dysfunction 1Central Nervous System Neoplasms 1Cardiomyopathies 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Atherosclerosis 1

Interventions

Hematologic Tests 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Dyspnea × Echocardiography × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡